ARWR Slides 17% as Shorts Build and the Street Holds Its Ground

The Street is notably more constructive than the tape suggests, which creates a visible gap worth sitting with. Citigroup's Eric Joseph initiated coverage on September 8 with a Buy and a $108 target — almost 53% above the current price. That follows a cluster of analysts who raised targets through late July: Morgan Stanley lifted to $120, Piper Sandler went to $126, and B. Riley took its target from $101 to $123. The consensus mean target is now $110, representing roughly 56% implied upside from current levels. The bull case centres on plozasiran's potential as a first-in-class treatment for severe hypertriglyceridemia, with a clean clinical profile and a pipeline broad enough to span cardiology, liver disease, and pulmonology. Bears flag the more familiar biotech risks — the company is still pre-profitability, carries a deeply negative EPS yield, and the EV/EBITDA ratio is negative, reflecting cash burn rather than earnings. The price-to-book multiple of 44x underscores how much of the valuation is built on pipeline optionality rather than current assets. ARWR's analyst recommendation factor ranks in the 92nd percentile of the ORTEX universe — the Street is overwhelmingly constructive. The disconnect between that positioning and where the stock is trading this week is the central tension.

One feature of the ownership register worth flagging: Sarepta Therapeutics filed a Schedule 13D/A on this stock in August 2025, making it an activist-class holder under SEC rules. Sarepta's most recently disclosed stake was 9.5% of shares outstanding, though that figure is from the last disclosure and positions at this level can change without further filings if the holder drops below 5%. As the standard disclosure caveat applies — stakes are as-last-disclosed around the 5% threshold — the current position cannot be confirmed. Sarepta's presence on the register has historically reflected a strategic interest in Arrowhead's RNAi platform rather than financial activism, but the 13D classification is notable. Separately, institutional flows are broadly positive: BlackRock added roughly 140,000 shares in the most recent reporting period, Fidelity added 771,000, and Avoro Capital — a dedicated biotech fund holding 8% of shares — added 655,000 shares in its last disclosure. The seller in the near term appears to be the market rather than the long-term holders.

The next scheduled earnings event is November 25. Given that the two most recent quarterly prints produced muted single-digit one-day moves — up 2.9% in August and up 1.0% in early August — the stock has not historically been a large earnings mover. What changes that calculus is clinical readout timing: plozasiran's regulatory path and any pipeline data packages between now and November are the variables that will determine whether the 55% gap between the current price and the analyst mean target begins to close — or widens further.